Rocket Pharmaceuticals (NASDAQ:RCKT) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03, MarketWatch Earnings reports.
Shares of RCKT stock traded down $0.98 during trading hours on Thursday, reaching $17.46. 231,675 shares of the company’s stock were exchanged, compared to its average volume of 226,722. Rocket Pharmaceuticals has a 1 year low of $7.84 and a 1 year high of $25.96. The company has a debt-to-equity ratio of 0.25, a current ratio of 13.27 and a quick ratio of 13.27.
Several research firms have commented on RCKT. William Blair reaffirmed a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Wednesday. Zacks Investment Research raised Rocket Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Finally, LADENBURG THALM/SH SH began coverage on Rocket Pharmaceuticals in a research note on Thursday, September 13th. They set a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $28.50.
ILLEGAL ACTIVITY NOTICE: “Rocket Pharmaceuticals (RCKT) Issues Quarterly Earnings Results” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/11/08/rocket-pharmaceuticals-rckt-issues-quarterly-earnings-results.html.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.